Polygenic Risk Score: Clinically Useful Tool for Prediction of Cardiovascular Disease and Benefit from Lipid-Lowering Therapy?

Published on Jun 1, 2021in Cardiovascular Drugs and Therapy4.069
· DOI :10.1007/S10557-020-07105-7
Natalie Arnold1
Estimated H-index: 1
(UHH: University of Hamburg),
Natalie Arnold7
Estimated H-index: 7
Wolfgang Koenig34
Estimated H-index: 34
(TUM: Technische Universität München)
Improvement in risk prediction of atherosclerotic cardiovascular disease (ASCVD) using information on the genetic predisposition at an individual level might offer new possibilities for the successful management of such complex trait. Latest developments in genetic research with the conduction of genome-wide association studies have facilitated a broader utility of polygenic risk score (PRS) as a potent risk prognosticator, being strongly associated with future cardiovascular events. Although its discriminative ability beyond traditional risk factors is still a matter of controversy, PRS possesses at least comparable risk information to that provided by traditional risk tools. More importantly, increased genetic risk for ASCVD might be discovered at younger ages, much longer before conventional risk factors become manifest, thereby providing a potent instrument for aggressive primordial and primary prevention in those at high risk. Furthermore, there is strong evidence that inherited risk may be successfully modulated by a healthy lifestyle or medication use (e.g., statins or PCSK-9 inhibitors). Here, we provide a short overview of the current research related to the possible application of PRS in clinical routine and critically discuss existing pitfalls, which still limit a widespread utility of PRS outside a research setting.
#1Chantal Babb de Villiers (University of Cambridge)H-Index: 6
#2Mark Kroese (University of Cambridge)H-Index: 1
Last. Sowmiya Moorthie (University of Cambridge)H-Index: 9
view all 3 authors...
The use of genomic information to better understand and prevent common complex diseases has been an ongoing goal of genetic research. Over the past few years, research in this area has proliferated with several proposed methods of generating polygenic scores. This has been driven by the availability of larger data sets, primarily from genome-wide association studies and concomitant developments in statistical methodologies. Here we provide an overview of the methodological aspects of polygenic m...
3 CitationsSource
An individual’s susceptibility to atherosclerotic cardiovascular disease is influenced by numerous clinical and lifestyle factors, motivating the multifaceted approaches currently endorsed for prim...
26 CitationsSource
#1Amy Damask (Regeneron)H-Index: 2
#1Amy Damask (Regeneron)H-Index: 1
Last. Charles Paulding (Regeneron)H-Index: 1
view all 20 authors...
Background: Alirocumab, an antibody that blocks proprotein convertase subtilisin/kexin type 9 (PCSK9), was associated with reduced major adverse cardiovascular events (MACE) and death in the ODYSSE...
52 CitationsSource
#1Nicholas A Marston (Brigham and Women's Hospital)H-Index: 8
#2Frederick K. Kamanu (Brigham and Women's Hospital)H-Index: 5
Last. Christian T. Ruff (Brigham and Women's Hospital)H-Index: 46
view all 15 authors...
Background: The ability of a genetic risk score to predict risk in established cardiovascular disease and identify individuals who derive greater benefit from PCSK9 (proprotein convertase subtilisi...
50 CitationsSource
#1Jonathan D. Mosley (Vandy: Vanderbilt University)H-Index: 29
#2Deepak K. Gupta (VUMC: Vanderbilt University Medical Center)H-Index: 26
Last. Thomas J. Wang (UTSW: University of Texas Southwestern Medical Center)H-Index: 125
view all 16 authors...
Importance Polygenic risk scores comprising millions of single-nucleotide polymorphisms (SNPs) could be useful for population-wide coronary heart disease (CHD) screening. Objective To determine whether a polygenic risk score improves prediction of CHD compared with a guideline-recommended clinical risk equation. Design, Setting, and Participants A retrospective cohort study of the predictive accuracy of a previously validated polygenic risk score was assessed among 4847 adults of white European ...
83 CitationsSource
#1Joshua Elliott (Imperial College London)H-Index: 9
#2Barbara Bodinier (Imperial College London)H-Index: 7
Last. Ioanna Tzoulaki (Imperial College London)H-Index: 69
view all 10 authors...
Importance The incremental value of polygenic risk scores in addition to well-established risk prediction models for coronary artery disease (CAD) is uncertain. Objective To examine whether a polygenic risk score for CAD improves risk prediction beyond pooled cohort equations. Design, Setting, and Participants Observational study of UK Biobank participants enrolled from 2006 to 2010. A case-control sample of 15 947 prevalent CAD cases and equal number of age and sex frequency–matched controls wa...
86 CitationsSource
#1Natalie Arnold (University of Mainz)H-Index: 7
#2Wolfgang Koenig (TUM: Technische Universität München)H-Index: 129
Last. Wolfgang Koenig (TUM: Technische Universität München)H-Index: 34
view all 2 authors...
PURPOSE OF REVIEW: To briefly summarize recently published evidence in the field of cardiovascular proteomics, focusing on its ability to improve cardiovascular risk stratification and critically discussing still open and burning issues and future perspectives of proteomics research. RECENT FINDINGS: Several epidemiological studies have demonstrated an improvement in cardiovascular risk prediction beyond traditional risk factors by adding novel biomarkers, identified by both discovery and target...
3 CitationsSource
#1George HindyH-Index: 20
#2Krishna G. AragamH-Index: 21
Last. Sekar KathiresanH-Index: 137
view all 7 authors...
Genome-wide polygenic scores for coronary artery disease (GPSCAD) integrate information from millions of common DNA polymorphisms into a single measure of inherited susceptibility. The incremental ...
3 Citations
#1Scott M. GrundyH-Index: 212
#1Scott M. GrundyH-Index: 77
Last. Joseph YeboahH-Index: 29
view all 24 authors...
Glenn N. Levine, MD, FACC, FAHA, Chair Patrick T. O’Gara, MD, MACC, FAHA, Chair-Elect Jonathan L. Halperin, MD, FACC, FAHA, Immediate Past Chair [‡‡‡][1] Sana M. Al-Khatib, MD, MHS, FACC, FAHA Joshua A. Beckman, MD, MS, FAHA Kim K. Birtcher, PharmD, MS, AACC Biykem Bozkurt, MD, PhD,
1,671 CitationsSource
732 CitationsSource
Cited By2
#1Nicola Rares Franco (Ghent University Hospital)H-Index: 1
#1Nicola Rares Franco (Ghent University Hospital)
Last. Tiziana RancatiH-Index: 27
view all 120 authors...
AIM To identify the effect of single nucleotide polymorphism (SNP) interactions on the risk of toxicity following radiotherapy (RT) for prostate cancer (PCa) and propose a new method for polygenic risk score incorporating SNP-SNP interactions (PRSi). MATERIALS AND METHODS Analysis included the REQUITE PCa cohort that received external beam RT and was followed for 2 years. Late toxicity endpoints were: rectal bleeding, urinary frequency, haematuria, nocturia, decreased urinary stream. Among 43 li...